O
PPBT

OrbiMed’s Purple Biotech PPBT Stock Holding History

OrbiMed’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-89
Closed -$86K – 183
2021
Q2 		$86K Sell
89
-68
-43% -$62.5K ﹤0.01% 159
2021
Q1 		$130K Sell
157
-1,574
-91% -$1.47M ﹤0.01% 157
2020
Q4 		$1.32M Hold
1,731
– – 0.01% 146
2020
Q3 		$1.53M Hold
1,731
– – 0.02% 137
2020
Q2 		$3.84M Hold
1,731
– – 0.05% 124
2020
Q1 		$1.06M Buy
+1,731
New +$2.12M 0.02% 133

Other funds holding PPBT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
WTB
Washington Trust Bank Spokane, Washington $1.36B AUM 21.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return

OrbiMed's PPBT Position: Q3 2021 in Review

OrbiMed sold out of Purple Biotech (PPBT) in Q3 2021, closing a stake of 89 shares — an estimated $86K sold.

OrbiMed first reported a position in PPBT in Q1 2020 and held it in 6 quarters. The position peaked at $3.84M in Q2 2020. 11 funds tracked by Wall St. Rank hold PPBT as of Q3 2021.

  • OrbiMed reported no remaining Purple Biotech position as of Q3 2021 after selling out during the quarter.
  • OrbiMed sold 89 Purple Biotech shares in Q3 2021, an estimated $86K.
  • OrbiMed first reported a position in Purple Biotech in Q1 2020 and held it in 6 quarters.
  • OrbiMed's Purple Biotech position peaked at $3.84M in Q2 2020.
  • 11 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.